ASH 2017 | Curative strategy for smoldering multiple myeloma: GEM-CESAR

Maria-Victoria Mateos

In this exciting interview from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Maria-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain, discusses the GEM-CESAR study (NCT02415413). This trial investigates a curative strategy for high-risk smoldering multiple myeloma (SMM), consisting of induction with carfilzomib, lenalidomide and dexamethasone (KRd), followed by HDT-ASCT, consolidation with KRd and maintenance with Rd. Dr Mateos discusses the logic behind this strategy, the results of the study in terms of progression to MM, response rates, MRD, overall survival and the safety profile of the regimen.

Share this video